These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 16309985)

  • 21. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
    Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
    J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Macrophage lineage phenotypes and osteoclastogenesis--complexity in the control by GM-CSF and TGF-beta.
    Lari R; Fleetwood AJ; Kitchener PD; Cook AD; Pavasovic D; Hertzog PJ; Hamilton JA
    Bone; 2007 Feb; 40(2):323-36. PubMed ID: 17055352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
    Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
    Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human interleukin-1-induced murine osteoclastogenesis is dependent on RANKL, but independent of TNF-alpha.
    Ma T; Miyanishi K; Suen A; Epstein NJ; Tomita T; Smith RL; Goodman SB
    Cytokine; 2004 May; 26(3):138-44. PubMed ID: 15135808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
    Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
    Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms involved in the enhancement of osteoclast formation by enamel matrix derivative.
    Itoh N; Kasai H; Ariyoshi W; Harada E; Yokota M; Nishihara T
    J Periodontal Res; 2006 Aug; 41(4):273-9. PubMed ID: 16827720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts.
    Kindle L; Rothe L; Kriss M; Osdoby P; Collin-Osdoby P
    J Bone Miner Res; 2006 Feb; 21(2):193-206. PubMed ID: 16418775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
    Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
    J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation.
    Smith R; Ransjö M; Tatarczuch L; Song SJ; Pagel C; Morrison JR; Pike RN; Mackie EJ
    J Bone Miner Res; 2004 Mar; 19(3):507-16. PubMed ID: 15040840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
    Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mechanism of osteoclast differentiation induced by IL-1.
    Kim JH; Jin HM; Kim K; Song I; Youn BU; Matsuo K; Kim N
    J Immunol; 2009 Aug; 183(3):1862-70. PubMed ID: 19587010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TGF-beta enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF.
    Sells Galvin RJ; Gatlin CL; Horn JW; Fuson TR
    Biochem Biophys Res Commun; 1999 Nov; 265(1):233-9. PubMed ID: 10548519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
    Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
    Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
    Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
    Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
    Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
    J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mitogen-activated protein kinases mediate interleukin-1beta-induced receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells.
    Oikawa A; Kobayashi M; Okamatsu Y; Shinki T; Kamijo R; Yamamoto M; Hasegawa K
    J Periodontal Res; 2007 Aug; 42(4):367-76. PubMed ID: 17559635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis.
    Merle B; Itzstein C; Delmas PD; Chenu C
    J Cell Biochem; 2003 Oct; 90(2):424-36. PubMed ID: 14505357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
    Dai SM; Nishioka K; Yudoh K
    Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
    J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.